Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 5/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.34 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | CHUK | O15111 | 2/20 | 0.32 |
| ▸ | PRF1 | P14222 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725831 | 1.00 | ALOX5 (0.34) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL6832582 | 0.86 | PTGS1 (0.36) | ALOX5PTGS1PTGS2 | |
| SCHEMBL2745819 | 0.84 | CYP3A4 (0.43) | PIP4K2APIP4K2BCYP3A4PRF1BRD4 | |
| SCHEMBL2745821 | 0.84 | CYP3A4 (0.43) | PIP4K2APIP4K2BCYP3A4PRF1BRD4 | |
| SCHEMBL2128431 | 0.83 | CYP3A4 (0.49) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL1543810 | 0.83 | CYP3A4 (0.49) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL2745732 | 0.81 | CYP3A4 (0.38) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL2745734 | 0.81 | CYP3A4 (0.38) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL1542782 | 0.80 | CYP3A4 (0.37) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B | |
| SCHEMBL2128776 | 0.80 | CYP3A4 (0.37) | ALOX5PTGS1PTGS2PIP4K2APIP4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8158803-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2421831-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010122082-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LEE EUN KYUNG | 2010-10-28 | — | — | US | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272677-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, RRM2B | ALOX5 3133/4885PTGS1 1315/4885PTGS2 2288/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | ALOX5 3874/4885PTGS1 1895/4885PTGS2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.